Arcus Biosciences, Inc.
RCUS · XNYSCIK 1724521fmd_1YM8AMKHB04YDH34EFESZGTR01Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2016 to Sep 30, 2026, 40 periods
Latest annual · FY2025
Millions- Total revenues
- 247
- Operating income
- (386)
- Net income
- (353)
- Free cash flow
- (484)
Latest quarter · Q3 FY2026
Millions- Total revenues
- 9
- Operating income
- (131)
- Net income
- (128)
- Free cash flow
- (88)
Daily close · RCUSIEX trades only
Nov 13, 2025 to Nov 11, 2026 · 250 sessions18.80 USD
Built from trades executed at IEX only, one exchange with a small share of US volume. This is not the consolidated tape. The close is the last IEX trade of the session, not the official closing price. Earlier sessions are divided by the later split ratios the API confirmed against IEX prices; dividends are not adjusted. Switch to As traded for the prices as they printed. End of day, not real time: a session is published the day after it trades.
Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. iex.io/legal/hist-data-terms
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2022 to FY2025
- +30.2%
- Revenue, 5 yearsFY2020 to FY2025
- +25.9%
- Net income, 5 yearsFY2020 to FY2025
- n/m
Arcus Biosciences, Inc. (RCUS) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Revenue | $247 million | $258 million | -4.3% | 10-K 2026-02-25 · proof |
| Operating income | -$386 million | -$330 million | 10-K 2026-02-25 · proof | |
| Net income | -$353 million | -$283 million | 10-K 2026-02-25 · proof | |
| Cash from operating activities | -$482 million | -$170 million | 10-K 2026-02-25 · proof | |
| Free cash flow | -$484 million | -$176 million | 10-K 2026-02-25 · proof | |
| Total assets | $1.1 billion | $1.2 billion | -1% | 10-K 2026-02-25 · proof |
| Total liabilities | $508 million | $665 million | -23.6% | 10-K 2026-02-25 · proof |
| Cash and cash equivalents | $222 million | $150 million | +48% | 10-K 2026-02-25 · proof |
- What was Arcus Biosciences, Inc. (RCUS)'s revenue in fiscal 2025?
- Arcus Biosciences, Inc. (RCUS) reported revenue of $247 million for fiscal 2025 (the year ended Dec 31, 2025), against $258 million the year before (-4.3%). Source: the 10-K filed with the SEC on Feb 25, 2026. SEC
- What was Arcus Biosciences, Inc. (RCUS)'s operating income in fiscal 2025?
- Arcus Biosciences, Inc. (RCUS) reported operating income of -$386 million for fiscal 2025 (the year ended Dec 31, 2025), against -$330 million the year before. Source: the 10-K filed with the SEC on Feb 25, 2026. SEC
- What was Arcus Biosciences, Inc. (RCUS)'s net income in fiscal 2025?
- Arcus Biosciences, Inc. (RCUS) reported net income of -$353 million for fiscal 2025 (the year ended Dec 31, 2025), against -$283 million the year before. Source: the 10-K filed with the SEC on Feb 25, 2026. SEC
- What was Arcus Biosciences, Inc. (RCUS)'s cash from operating activities in fiscal 2025?
- Arcus Biosciences, Inc. (RCUS) reported cash from operating activities of -$482 million for fiscal 2025 (the year ended Dec 31, 2025), against -$170 million the year before. Source: the 10-K filed with the SEC on Feb 25, 2026. SEC
- What was Arcus Biosciences, Inc. (RCUS)'s free cash flow in fiscal 2025?
- Arcus Biosciences, Inc. (RCUS) reported free cash flow of -$484 million for fiscal 2025 (the year ended Dec 31, 2025), against -$176 million the year before. Source: the 10-K filed with the SEC on Feb 25, 2026. SEC
- What are Arcus Biosciences, Inc. (RCUS)'s total assets?
- As of Dec 31, 2025, Arcus Biosciences, Inc. (RCUS) reported total assets of $1.1 billion, against $1.2 billion a year earlier (-1%). Source: the 10-K filed with the SEC on Feb 25, 2026. SEC
- What are Arcus Biosciences, Inc. (RCUS)'s total liabilities?
- As of Dec 31, 2025, Arcus Biosciences, Inc. (RCUS) reported total liabilities of $508 million, against $665 million a year earlier (-23.6%). Source: the 10-K filed with the SEC on Feb 25, 2026. SEC
- What are Arcus Biosciences, Inc. (RCUS)'s cash and cash equivalents?
- As of Dec 31, 2025, Arcus Biosciences, Inc. (RCUS) reported cash and cash equivalents of $222 million, against $150 million a year earlier (+48%). Source: the 10-K filed with the SEC on Feb 25, 2026. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:RCUS&period_type=annual&limit=5"Information only, not investment advice.